Your browser doesn't support javascript.
loading
Oral rimegepant for preventive treatment of migraine: a phase 2/3, randomised, double-blind, placebo-controlled trial.
Croop, Robert; Lipton, Richard B; Kudrow, David; Stock, David A; Kamen, Lisa; Conway, Charles M; Stock, Elyse G; Coric, Vladimir; Goadsby, Peter J.
Afiliação
  • Croop R; Biohaven Pharmaceuticals, New Haven, CT, USA. Electronic address: robert.croop@biohavenpharma.com.
  • Lipton RB; Department of Neurology, Albert Einstein College of Medicine, Bronx, NY, USA.
  • Kudrow D; California Medical Clinic for Headache, Santa Monica, CA, USA.
  • Stock DA; Biohaven Pharmaceuticals, New Haven, CT, USA.
  • Kamen L; Biohaven Pharmaceuticals, New Haven, CT, USA.
  • Conway CM; Biohaven Pharmaceuticals, New Haven, CT, USA.
  • Stock EG; Biohaven Pharmaceuticals, New Haven, CT, USA.
  • Coric V; Biohaven Pharmaceuticals, New Haven, CT, USA.
  • Goadsby PJ; NIHR-Wellcome Trust King's Clinical Research Facility, King's College Hospital/SLaM Biomedical Research Centre, King's College London, UK; University of California, Los Angeles, Los Angeles, CA, USA.
Lancet ; 397(10268): 51-60, 2021 01 02.
Article em En | MEDLINE | ID: mdl-33338437
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Piperidinas / Piridinas / Antagonistas do Receptor do Peptídeo Relacionado ao Gene de Calcitonina / Transtornos de Enxaqueca Tipo de estudo: Clinical_trials Limite: Adult / Female / Humans / Male Idioma: En Ano de publicação: 2021 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Piperidinas / Piridinas / Antagonistas do Receptor do Peptídeo Relacionado ao Gene de Calcitonina / Transtornos de Enxaqueca Tipo de estudo: Clinical_trials Limite: Adult / Female / Humans / Male Idioma: En Ano de publicação: 2021 Tipo de documento: Article